Serigne Lo
YOU?
Author Swipe
View article: A cost comparison of radiotherapy and topical imiquimod for lentigo maligna treatment: Considerations for clinical decision-making
A cost comparison of radiotherapy and topical imiquimod for lentigo maligna treatment: Considerations for clinical decision-making Open
Imiquimod represents a substantially more cost-effective treatment option for managing LM compared with radiotherapy. Patient-centered shared decision-making should be prioritized.
View article: Pathological response calculation assessment remains accurate with reduced tumor bed examination after neoadjuvant immunotherapy in clinically detectable stage III melanoma
Pathological response calculation assessment remains accurate with reduced tumor bed examination after neoadjuvant immunotherapy in clinically detectable stage III melanoma Open
TB embedded for histopathological examination in neoadjuvant stage IIIB/C/D melanoma specimens can be reduced without significantly compromising accuracy of %RVT calculation. We recommend an updated pathological assessment protocol: lymph …
View article: Study protocol of a randomised phase II trial of concurrent stereotactic body radiotherapy with immunotherapy versus immunotherapy alone in patients with 1–5 extracranial melanoma oligometastases (AXIOM)
Study protocol of a randomised phase II trial of concurrent stereotactic body radiotherapy with immunotherapy versus immunotherapy alone in patients with 1–5 extracranial melanoma oligometastases (AXIOM) Open
ClinicalTrials.gov: NCT06767306.
View article: Evaluating educational interventions on healthcare students’ knowledge, attitudes, and practices (KAP) towards One Health in Hong Kong
Evaluating educational interventions on healthcare students’ knowledge, attitudes, and practices (KAP) towards One Health in Hong Kong Open
Background: One Health is a multidisciplinary framework that recognises the interconnectedness of human, animal, and environmental health. Despite its importance, One Health education in Hong Kong is relatively limited when compared to oth…
View article: Table S1 from Discovery and Validation of an Ancillary Genomic Test of Malignancy for Primary Melanocytic Tumors
Table S1 from Discovery and Validation of an Ancillary Genomic Test of Malignancy for Primary Melanocytic Tumors Open
Clinical-pathological features and sequencing metrics for each sample in the investigative cohort.
View article: Table S3 from Discovery and Validation of an Ancillary Genomic Test of Malignancy for Primary Melanocytic Tumors
Table S3 from Discovery and Validation of an Ancillary Genomic Test of Malignancy for Primary Melanocytic Tumors Open
Copy number alteration metrics for each sample in the investigative cohort.
View article: Supplementary Results1 from Discovery and Validation of an Ancillary Genomic Test of Malignancy for Primary Melanocytic Tumors
Supplementary Results1 from Discovery and Validation of an Ancillary Genomic Test of Malignancy for Primary Melanocytic Tumors Open
Supplementary Results
View article: Table S16 from Discovery and Validation of an Ancillary Genomic Test of Malignancy for Primary Melanocytic Tumors
Table S16 from Discovery and Validation of an Ancillary Genomic Test of Malignancy for Primary Melanocytic Tumors Open
Patients with borderline conventional tumors and available clinical followup
View article: Table S14 from Discovery and Validation of an Ancillary Genomic Test of Malignancy for Primary Melanocytic Tumors
Table S14 from Discovery and Validation of an Ancillary Genomic Test of Malignancy for Primary Melanocytic Tumors Open
Clinical, pathological and genomic features for Tier 2 borderline conventional tumors with high probability of melanoma. Additional ancillary test results are included when available from the patients’ report. Catalogue of Somatic Mutation…
View article: Table S6 from Discovery and Validation of an Ancillary Genomic Test of Malignancy for Primary Melanocytic Tumors
Table S6 from Discovery and Validation of an Ancillary Genomic Test of Malignancy for Primary Melanocytic Tumors Open
Clinical and pathological characteristics of melanomas and nevi in discovery and validation cohorts.
View article: Table S9 from Discovery and Validation of an Ancillary Genomic Test of Malignancy for Primary Melanocytic Tumors
Table S9 from Discovery and Validation of an Ancillary Genomic Test of Malignancy for Primary Melanocytic Tumors Open
Clinical-pathological features, detected mutations and probability of melanoma for nevi with high predicted scores.
View article: Table S10 from Discovery and Validation of an Ancillary Genomic Test of Malignancy for Primary Melanocytic Tumors
Table S10 from Discovery and Validation of an Ancillary Genomic Test of Malignancy for Primary Melanocytic Tumors Open
Clinical-pathological features and sequencing metrics for each sample in the borderline cohort.
View article: Figure S1 from Discovery and Validation of an Ancillary Genomic Test of Malignancy for Primary Melanocytic Tumors
Figure S1 from Discovery and Validation of an Ancillary Genomic Test of Malignancy for Primary Melanocytic Tumors Open
Scatter plot of mean target coverage and mean number of unique start sites across targets for melanomas and nevi in the investigative cohort. Samples with a coverage below 300X (square shape) were deemed outliers and removed from further a…
View article: Table S13 from Discovery and Validation of an Ancillary Genomic Test of Malignancy for Primary Melanocytic Tumors
Table S13 from Discovery and Validation of an Ancillary Genomic Test of Malignancy for Primary Melanocytic Tumors Open
Predicted probability of melanoma of the bivariate genomic model in borderline conventional tumors.
View article: Table S12 from Discovery and Validation of an Ancillary Genomic Test of Malignancy for Primary Melanocytic Tumors
Table S12 from Discovery and Validation of an Ancillary Genomic Test of Malignancy for Primary Melanocytic Tumors Open
Copy number alteration metrics for each sample in the borderline cohort.
View article: Figure S3 from Discovery and Validation of an Ancillary Genomic Test of Malignancy for Primary Melanocytic Tumors
Figure S3 from Discovery and Validation of an Ancillary Genomic Test of Malignancy for Primary Melanocytic Tumors Open
Distribution of total, coding and non-coding mutational load against pathological and clinical features. (A) Distribution in melanomas. (B) Distribution in nevi. LOESS regression is shown in blue for thickness, TMR and age at biopsy. NS: N…
View article: Table S15 from Discovery and Validation of an Ancillary Genomic Test of Malignancy for Primary Melanocytic Tumors
Table S15 from Discovery and Validation of an Ancillary Genomic Test of Malignancy for Primary Melanocytic Tumors Open
Ancillary tests results for patients with borderline tumors
View article: Figure S5 from Discovery and Validation of an Ancillary Genomic Test of Malignancy for Primary Melanocytic Tumors
Figure S5 from Discovery and Validation of an Ancillary Genomic Test of Malignancy for Primary Melanocytic Tumors Open
Histomorphology of two ‘nevi’ in the investigative cohort with high bivariate genomic model scores. NAE2 shows an asymmetrical compound tumor on low power (A), with irregular sized nests of melanocytes at the dermoepidermal junction and in…
View article: Table S11 from Discovery and Validation of an Ancillary Genomic Test of Malignancy for Primary Melanocytic Tumors
Table S11 from Discovery and Validation of an Ancillary Genomic Test of Malignancy for Primary Melanocytic Tumors Open
Somatic point mutations and indels for each sample in the borderline cohort.
View article: Table S7 from Discovery and Validation of an Ancillary Genomic Test of Malignancy for Primary Melanocytic Tumors
Table S7 from Discovery and Validation of an Ancillary Genomic Test of Malignancy for Primary Melanocytic Tumors Open
Performance metrics for individual genes and mutational loads.
View article: Data from Discovery and Validation of an Ancillary Genomic Test of Malignancy for Primary Melanocytic Tumors
Data from Discovery and Validation of an Ancillary Genomic Test of Malignancy for Primary Melanocytic Tumors Open
Purpose:Pathologic diagnosis of melanocytic tumors can be difficult and prone to error. More accurate ancillary tools are needed. We present a genomic model for distinguishing benign (nevi) from malignant (melanoma) melanocytic skin tumors…
View article: Table S4 from Discovery and Validation of an Ancillary Genomic Test of Malignancy for Primary Melanocytic Tumors
Table S4 from Discovery and Validation of an Ancillary Genomic Test of Malignancy for Primary Melanocytic Tumors Open
Mutational load and mutational status for each sample in the investigative cohort.
View article: Figure S2 from Discovery and Validation of an Ancillary Genomic Test of Malignancy for Primary Melanocytic Tumors
Figure S2 from Discovery and Validation of an Ancillary Genomic Test of Malignancy for Primary Melanocytic Tumors Open
Mutational load in melanomas and nevi from the investigative cohort. (A) Mutational load in melanomas and nevi by mutational load type. (B) Mutational load in melanomas stratified by driver mutation and mutational load type. NS: Not Signif…
View article: Table S8 from Discovery and Validation of an Ancillary Genomic Test of Malignancy for Primary Melanocytic Tumors
Table S8 from Discovery and Validation of an Ancillary Genomic Test of Malignancy for Primary Melanocytic Tumors Open
Predicted probability of melanoma of the bivariate genomic model in discovery and validation.
View article: Table S5 from Discovery and Validation of an Ancillary Genomic Test of Malignancy for Primary Melanocytic Tumors
Table S5 from Discovery and Validation of an Ancillary Genomic Test of Malignancy for Primary Melanocytic Tumors Open
Statistical association tests of clinical-pathological features against mutational loads.
View article: Table S2 from Discovery and Validation of an Ancillary Genomic Test of Malignancy for Primary Melanocytic Tumors
Table S2 from Discovery and Validation of an Ancillary Genomic Test of Malignancy for Primary Melanocytic Tumors Open
Somatic point mutations and indels for each sample in the investigative cohort.
View article: Figure S6 from Discovery and Validation of an Ancillary Genomic Test of Malignancy for Primary Melanocytic Tumors
Figure S6 from Discovery and Validation of an Ancillary Genomic Test of Malignancy for Primary Melanocytic Tumors Open
Examples of two dermal nevi (A – NAE79, B – NAE52) with solar elastosis and low bivariate genomic model scores (<0.1).
View article: Figure S7 from Discovery and Validation of an Ancillary Genomic Test of Malignancy for Primary Melanocytic Tumors
Figure S7 from Discovery and Validation of an Ancillary Genomic Test of Malignancy for Primary Melanocytic Tumors Open
Scatter plot of mean target coverage and mean number of unique start sites across targets for borderline melanocytic tumors. Samples with a coverage below 300X (square shape) were deemed outliers and removed from further analysis.
View article: Figure S4 from Discovery and Validation of an Ancillary Genomic Test of Malignancy for Primary Melanocytic Tumors
Figure S4 from Discovery and Validation of an Ancillary Genomic Test of Malignancy for Primary Melanocytic Tumors Open
Boxplot of scores from the bivariate genomic model in discovery and validation. The optimal cut-off that maximises the difference between true positive rate (TPR) and false positive rate (FPR) corresponding to the Youden index is identifie…